Reports Q3 revenue $170.992M, consensus $162.99M. “Axsome posted strong revenue growth in the third quarter driven by contributions from all three of our marketed products,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics (AXSM). “Our broad development pipeline continues to advance, and we recently submitted our supplemental NDA for AXS-05 for the treatment of Alzheimer’s disease agitation, a serious condition affecting millions of patients in the U.S., and a critical unmet medical need. With robust commercial performance and pipeline execution, Axsome is well positioned to continue delivering substantial and sustained growth and transformative new medicines for patients living with serious CNS disorders.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Is AXSM a Buy, Before Earnings?
- Axsome Therapeutics Advances Study on Solriamfetol for Binge Eating Disorder
- Axsome Therapeutics’ Promising Phase 3 Trial for Shift Work Disorder
- Axsome Therapeutics’ AXS-05 Study: A Potential Game-Changer for MDD Relapse Prevention
- Axsome Therapeutics Advances Phase 3 Trial for Binge Eating Disorder Treatment